Related references
Note: Only part of the references are listed.Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy
Jingwei Chen et al.
CLINICAL CANCER RESEARCH (2021)
BRD4-mediated repression of p53 is a target for combination therapy in AML
Anne-Louise Latif et al.
NATURE COMMUNICATIONS (2021)
The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs
Amanda C. Sharko et al.
CELLS (2021)
Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
Zuzana Tothova et al.
JCI INSIGHT (2021)
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma
Warren Fiskus et al.
LEUKEMIA (2021)
Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma
Wei Zhang et al.
CANCER LETTERS (2020)
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma
Samuel C. Fehling et al.
CANCER LETTERS (2020)
Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Jiajun Zhang et al.
CLINICAL CANCER RESEARCH (2020)
JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer
Tina Bagratuni et al.
EUROPEAN JOURNAL OF CANCER (2020)
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
Emily J. Faivre et al.
NATURE (2020)
Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer
Stanley Zhou et al.
NATURE COMMUNICATIONS (2020)
A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells
Lei Guo et al.
NATURE COMMUNICATIONS (2020)
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors
Dyana T. Saenz et al.
BLOOD (2020)
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers
Stephanie L. Guerra et al.
CANCER CELL (2020)
Redundant and specific roles of cohesin STAG subunits in chromatin looping and transcriptional control
Valentina Casa et al.
GENOME RESEARCH (2020)
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Omer Gilan et al.
SCIENCE (2020)
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
Jennifer Y. Ge et al.
NATURE COMMUNICATIONS (2020)
Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Chevaun D. Morrison-Smiths et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Opposing Functions of BRD4 Isoforms in Breast Cancer
Shwu-Yuan Wu et al.
MOLECULAR CELL (2020)
Roles of the BRD4 short isoform in phase separation and active gene transcription
Xinye Han et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)
Co-inhibition of BET proteins and PI3Kα triggers mitochondrial apoptosis in rhabdomyosarcoma cells
Cathinka Boedicker et al.
ONCOGENE (2020)
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
V Moreno et al.
ANNALS OF ONCOLOGY (2020)
BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells
Simona Camero et al.
CANCER LETTERS (2020)
Place Yours BETs in Combination Therapy
Brian J. Liddicoat et al.
MOLECULAR CELL (2020)
Partitioning of cancer therapeutics in nuclear condensates
Isaac A. Klein et al.
SCIENCE (2020)
Highly interconnected enhancer communities control lineage-determining genes in human mesenchymal stem cells
Jesper G. S. Madsen et al.
NATURE GENETICS (2020)
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
Sarina A. Piha-Paul et al.
JNCI CANCER SPECTRUM (2020)
Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma
Grazia Ambrosini et al.
CANCER RESEARCH (2019)
COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer
Richard J. Fagan et al.
CANCER LETTERS (2019)
BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
Sujan Piya et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges
Scott D. Edmondson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor
Patrick Sin-Chan et al.
CANCER CELL (2019)
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Weiping Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
Pratiti Bandopadhayay et al.
NATURE COMMUNICATIONS (2019)
A Pliable Mediator Acts as a Functional Rather Than an Architectural Bridge between Promoters and Enhancers
Laila El Khattabi et al.
CELL (2019)
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Louise Walsh et al.
CLINICAL CANCER RESEARCH (2019)
Chromatin topology, condensates and gene regulation: shifting paradigms or just a phase?
Mustafa Mir et al.
DEVELOPMENT (2019)
A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells
Abir Arfaoui et al.
EMBO MOLECULAR MEDICINE (2019)
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Maria del Mar Noblejas-Lopez et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Decreased Enhancer-Promoter Proximity Accompanying Enhancer Activation
Nezha S. Benabdallah et al.
MOLECULAR CELL (2019)
BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells
David N. Debruyne et al.
NATURE (2019)
Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
William A. Flavahan et al.
NATURE (2019)
Dynamic lineage priming is driven via direct enhancer regulation by ERK
William B. Hamilton et al.
NATURE (2019)
Activity-by-contact model of enhancer-promoter regulation from thousands of CRISPR perturbations
Charles P. Fulco et al.
NATURE GENETICS (2019)
Brain cell type-specific enhancer-promoter interactome maps and disease-risk association
Alexi Nott et al.
SCIENCE (2019)
Identification and targeting of novel CDK9 complexes in acute myeloid leukemia
Elspeth M. Beauchamp et al.
BLOOD (2019)
Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma
Vivian Chua et al.
EMBO MOLECULAR MEDICINE (2019)
Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
Jean-Philippe Lambert et al.
MOLECULAR CELL (2019)
Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands
Florian Haller et al.
NATURE COMMUNICATIONS (2019)
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies
Matthew C. Stubbs et al.
CLINICAL CANCER RESEARCH (2019)
Regulatory functions of the Mediator kinases CDK8 and CDK19
Charli B. Fant et al.
TRANSCRIPTION-AUSTIN (2019)
Therapeutic targeting of transcriptional cyclin-dependent kinases
Matthew D. Galbraith et al.
TRANSCRIPTION-AUSTIN (2019)
BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
B. Sun et al.
LEUKEMIA (2018)
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Calla M. Olson et al.
NATURE CHEMICAL BIOLOGY (2018)
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Maria Rusan et al.
CANCER DISCOVERY (2018)
MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification
Mark W. Zimmerman et al.
CANCER DISCOVERY (2018)
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma
Amanda Balboni Iniguez et al.
CANCER CELL (2018)
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors
Jaclyn Andricovich et al.
CANCER CELL (2018)
EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins
Paradesi Naidu Gollavilli et al.
CANCER RESEARCH (2018)
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples
Han Chen et al.
CELL (2018)
CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia
John Anto Pulikkan et al.
CELL (2018)
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
Jonathan Welti et al.
CLINICAL CANCER RESEARCH (2018)
An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers
Melanie Mahe et al.
EMBO MOLECULAR MEDICINE (2018)
Assessing sufficiency and necessity of enhancer activities for gene expression and the mechanisms of transcription activation
Rui R. Catarino et al.
GENES & DEVELOPMENT (2018)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma
Xiaohui Zhang et al.
LEUKEMIA (2018)
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Hetal Patel et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Distinct roles of cohesin-SA1 and cohesin-SA2 in 3D chromosome organization
Aleksandar Kojic et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
Sara Bolin et al.
ONCOGENE (2018)
Coactivator condensation at super-enhancers links phase separation and gene control
Benjamin R. Sabari et al.
SCIENCE (2018)
Mediator and RNA polymerase II clusters associate in transcription-dependent condensates
Won-Ki Cho et al.
SCIENCE (2018)
Enhancer Logic and Mechanics in Development and Disease
Ryan Rickels et al.
TRENDS IN CELL BIOLOGY (2018)
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles
Fred C. Lam et al.
NATURE COMMUNICATIONS (2018)
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
Hatice Gulcin Ozer et al.
CANCER DISCOVERY (2018)
Distinct roles of cohesin-SA1 and cohesin-SA2 in 3D chromosome organization
Aleksandar Kojic et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is
Sida Liao et al.
GENES & DEVELOPMENT (2018)
DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4
Xin Jin et al.
MOLECULAR CELL (2018)
A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies
Carsten Bahr et al.
NATURE (2018)
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Tyler Risom et al.
NATURE COMMUNICATIONS (2018)
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
Amanda Balboni Iniguez et al.
CANCER CELL (2018)
Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains
Ann Boija et al.
CELL (2018)
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Hanghang Zhang et al.
CELL (2018)
Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma
Yan-Yi Jiang et al.
GUT (2017)
Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma
K. T. Siu et al.
LEUKEMIA (2017)
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
Ramiro Vazquez et al.
ONCOTARGET (2017)
The whole-genome landscape of medulloblastoma subtypes
Paul A. Northcott et al.
NATURE (2017)
Structures of transcription pre-initiation complex with TFIIH and Mediator
S. Schilbach et al.
NATURE (2017)
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
Xiangpeng Dai et al.
NATURE MEDICINE (2017)
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Andrea Piunti et al.
NATURE MEDICINE (2017)
Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition
Lu Yang et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
Florencia Cayrol et al.
NATURE COMMUNICATIONS (2017)
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex
Jon S. Zawistowski et al.
CANCER DISCOVERY (2017)
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer
Martina S. J. McDermott et al.
ONCOTARGET (2017)
Mice deficient of Myc super-enhancer region reveal differential control mechanism between normal and pathological growth
Kashyap Dave et al.
ELIFE (2017)
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
Ulrich Luecking et al.
CHEMMEDCHEM (2017)
Cohesin Loss Eliminates All Loop Domains
Suhas S. P. Rao et al.
CELL (2017)
Targeted Protein Degradation: from Chemical Biology to Drug Discovery
Philipp M. Cromm et al.
CELL CHEMICAL BIOLOGY (2017)
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer
Bo Li et al.
CANCER RESEARCH (2017)
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer
Ana S. Leal et al.
CANCER LETTERS (2017)
A Phase Separation Model for Transcriptional Control
Denes Hnisz et al.
CELL (2017)
Transcriptional Addiction in Cancer
James E. Bradner et al.
CELL (2017)
RNA Binding to CBP Stimulates Histone Acetylation and Transcription
Daniel A. Bose et al.
CELL (2017)
Insulator dysfunction and oncogene activation in IDH mutant gliomas
William A. Flavahan et al.
NATURE (2016)
Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers
Xiaoyang Zhang et al.
NATURE GENETICS (2016)
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yuhki Yokoyama et al.
CANCER RESEARCH (2016)
Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas
Davide Calebiro et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
Brian K. Albrecht et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu et al.
NATURE (2016)
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Tinghu Zhang et al.
NATURE CHEMICAL BIOLOGY (2016)
Potent and selective bivalent inhibitors of BET bromodomains
Michael J. Waring et al.
NATURE CHEMICAL BIOLOGY (2016)
An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma
Yotam Drier et al.
NATURE GENETICS (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Gene regulation at a distance: From remote enhancers to 3D regulatory ensembles
Francois Spitz
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
The role of pluripotency factors to drive stemness in gastrointestinal cancer
Martin Mueller et al.
STEM CELL RESEARCH (2016)
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Anastasios Stathis et al.
CANCER DISCOVERY (2016)
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
Alison M. Kurimchak et al.
Cell Reports (2016)
MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer
Christie C. Sze et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Cohesin Mutations in Cancer
Magali De Koninck et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases
Paul A. Clarke et al.
ELIFE (2016)
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Celine Berthon et al.
LANCET HAEMATOLOGY (2016)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim et al.
LANCET HAEMATOLOGY (2016)
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Michael Zengerle et al.
ACS CHEMICAL BIOLOGY (2015)
An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis
Smita Matkar et al.
CANCER CELL (2015)
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
Elias E. Stratikopoulos et al.
CANCER CELL (2015)
Genetic Control of Chromatin States in Humans Involves Local and Distal Chromosomal Interactions
Fabian Grubert et al.
CELL (2015)
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Yubao Wang et al.
CELL (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains
Artyom A. Alekseyenko et al.
GENES & DEVELOPMENT (2015)
Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers
Denes Hnisz et al.
MOLECULAR CELL (2015)
Mediator kinase inhibition further activates super-enhancer-associated genes in AML
Henry E. Pelish et al.
NATURE (2015)
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2015)
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert et al.
NATURE (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease
Trevor Dale et al.
NATURE CHEMICAL BIOLOGY (2015)
CTCF/cohesin-binding sites are frequently mutated in cancer
Riku Katainen et al.
NATURE GENETICS (2015)
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
Pawel K. Mazur et al.
NATURE MEDICINE (2015)
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development
Ana Ortega-Molina et al.
NATURE MEDICINE (2015)
Chromatin extrusion explains key features of loop and domain formation in wild-type and engineered genomes
Adrian L. Sanborn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape
Behnam Nabet et al.
CELL REPORTS (2015)
Resistance to everolimus driven by epigenetic regulation of MYC in ER plus breast cancers
Teeru Bihani et al.
ONCOTARGET (2015)
Regulatory Domains and Their Mechanisms
Nezha S. Benabdallah et al.
21ST CENTURY GENETICS: GENES AT WORK, VOL 80, 2015 (2015)
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Aristeidis Chaidos et al.
BLOOD (2014)
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Camilla L. Christensen et al.
CANCER CELL (2014)
Reactivation of Developmentally Silenced Globin Genes by Forced Chromatin Looping
Wulan Deng et al.
CELL (2014)
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Edmond Chipumuro et al.
CELL (2014)
A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping
Suhas S. P. Rao et al.
CELL (2014)
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia
Stefan Groeschel et al.
CELL (2014)
Cyclin-Dependent Kinase 7 Controls mRNA Synthesis by Affecting Stability of Preinitiation Complexes, Leading to Altered Gene Expression, Cell Cycle Progression, and Survival of Tumor Cells
Timothy W. R. Kelso et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
M. Affer et al.
LEUKEMIA (2014)
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Nicholas Kwiatkowski et al.
NATURE (2014)
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
Birgit Knoechel et al.
NATURE GENETICS (2014)
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Danielle Welter et al.
NUCLEIC ACIDS RESEARCH (2014)
In search of the determinants of enhancer-promoter interaction specificity
Joris van Arensbergen et al.
TRENDS IN CELL BIOLOGY (2014)
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
Bjoern Chapuy et al.
CANCER CELL (2013)
BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
Miguel F. Segura et al.
CANCER RESEARCH (2013)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Warren A. Whyte et al.
CELL (2013)
Super-Enhancers in the Control of Cell Identity and Disease
Denes Hnisz et al.
CELL (2013)
Architectural Protein Subclasses Shape 3D Organization of Genomes during Lineage Commitment
Jennifer E. Phillips-Cremins et al.
CELL (2013)
Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains
Guangtao Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Modification of Enhancer Chromatin: What, How, and Why?
Eliezer Calo et al.
MOLECULAR CELL (2013)
Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation
Wenbo Li et al.
NATURE (2013)
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation
Guangwu Guo et al.
NATURE GENETICS (2013)
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy
Cristina Balbas-Martinez et al.
NATURE GENETICS (2013)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
An integrated encyclopedia of DNA elements in the human genome
Ian Dunham et al.
NATURE (2012)
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Jesse R. Dixon et al.
NATURE (2012)
Spatial partitioning of the regulatory landscape of the X-inactivation centre
Elphege P. Nora et al.
NATURE (2012)
Selective requirement for Mediator MED23 in Ras-active lung cancer
Xu Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Epigenomic Enhancer Profiling Defines a Signature of Colon Cancer
Batool Akhtar-Zaidi et al.
SCIENCE (2012)
Systematic Localization of Common Disease-Associated Variation in Regulatory DNA
Matthew T. Maurano et al.
SCIENCE (2012)
Human Mediator Subunit MED26 Functions as a Docking Site for Transcription Elongation Factors
Hidehisa Takahashi et al.
CELL (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Phenotypic robustness conferred by apparently redundant transcriptional enhancers
Nicolas Frankel et al.
NATURE (2010)
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8
Avnish Kapoor et al.
NATURE (2010)
Widespread transcription at neuronal activity-regulated enhancers
Tae-Kyung Kim et al.
NATURE (2010)
Mediator and cohesin connect gene expression and chromatin architecture
Michael H. Kagey et al.
NATURE (2010)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
CDK8 is a positive regulator of transcriptional elongation within the serum response network
Aaron J. Donner et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
A Large Fraction of Extragenic RNA Pol II Transcription Sites Overlap Enhancers
Francesca De Santa et al.
PLOS BIOLOGY (2010)
The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
Simak Ali et al.
CANCER RESEARCH (2009)
TFIIH Kinase Places Bivalent Marks on the Carboxy-Terminal Domain of RNA Polymerase II
Md. Sohail Akhtar et al.
MOLECULAR CELL (2009)
MED1 phosphorylation promotes its association with Mediator: Implications for nuclear receptor signaling
Madesh Belakavadi et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Mediator-dependent recruitment of TFIIH modules in preinitiation complex
Cyril Esnault et al.
MOLECULAR CELL (2008)
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Ron Firestein et al.
NATURE (2008)
BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells
C. A. French et al.
ONCOGENE (2008)
Activation of TRAP/Mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation
PK Pandey et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Long-range chromatin regulatory interactions in vivo
D Carter et al.
NATURE GENETICS (2002)
Transcription control by E1A and MAP kinase pathway via Sur2 mediator subunit
JL Stevens et al.
SCIENCE (2002)
Enhancer-promoter specificity mediated by DPE or TATA core promoter motifs
JEF Butler et al.
GENES & DEVELOPMENT (2001)
Share Paper
